Web Stats Provided By Google Analytics

Friday, February 21, 2014

FDA punches BioMarin's 'golden ticket' for speedy drug review

Annabelle Bozarth started taking Vimizim, BioMarin Pharmaceutical's enzyme replacement therapy for MPS IVA, in a Phase III clinical trial.

http://ift.tt/1f5uEM9

No comments:

Post a Comment

Popular Healthcare Law Roundup Posts